Rheumatoid arthritis (RA) is one of the most consequential diagnoses a patient can receive — because what happens in the first 6–12 months of the disease largely determines how much joint damage will occur over the following decades. The immune system attacking the lining of the joints causes progressive erosion of cartilage and bone that, if untreated, leads to deformity and permanent disability. But with early diagnosis and the right disease-modifying medications, the majority of patients can achieve remission or low disease activity — living nearly normal lives with minimal joint damage.

At Suguna Clinic in Bandlaguda Jagir, Dr. Ram Kumar (MBBS, MD General Medicine, MPH USA) diagnoses RA using the standard ACR/EULAR clinical criteria and blood tests, initiates conventional DMARD therapy with methotrexate and hydroxychloroquine, monitors treatment response with disease activity assessment and blood tests, and ensures patients at more advanced stages of disease receive timely rheumatology referral for biological therapies when needed.

Rheumatoid Arthritis vs Osteoarthritis — A Critical Distinction

Many patients in Bandlaguda arrive at Suguna Clinic with joint pain that they — and sometimes their previous doctors — have labelled “arthritis” without specifying which type. This distinction matters enormously, because the two most common forms of arthritis have completely different causes, different affected populations, and completely different treatments.

Feature	Rheumatoid Arthritis (RA)	Osteoarthritis (OA)
Cause	Autoimmune — immune system attacks joints	Mechanical wear-and-tear of cartilage
Age of onset	Typically 30–60 years; can be younger	Typically above 50–60 years
Gender	3× more common in women	More common in women, both sexes
Morning stiffness	Prolonged — typically more than 1 hour	Brief — usually less than 30 minutes
Joints affected	Small joints of hands, feet, wrists — bilateral symmetrical	Weight-bearing joints: knees, hips, spine
Systemic symptoms	Fatigue, weight loss, anaemia, low fever	No systemic symptoms
Blood tests	RF, anti-CCP positive; elevated CRP and ESR	Normal blood tests
X-ray	Erosions, joint space narrowing in small joints	Osteophytes, joint space narrowing in large joints
Treatment	DMARDs (methotrexate, hydroxychloroquine) — slow disease	NSAIDs, physiotherapy, joint replacement

RA also needs to be distinguished from gout (acute, often single-joint, with uric acid crystals), post-chikungunya arthritis (follows chikungunya viral illness, usually self-limiting), psoriatic arthritis, and reactive arthritis. Dr. Ram Kumar takes a careful history and performs appropriate blood tests to establish the specific diagnosis before initiating treatment.

What Is Rheumatoid Arthritis? The Autoimmune Mechanism

RA is a systemic autoimmune disease in which the immune system — for reasons not entirely understood — mistakenly targets the synovium (the membrane lining joints) as a foreign threat. The immune attack causes synovial inflammation (synovitis), which produces joint swelling, warmth, and pain. Over time, the inflamed synovium (called “pannus”) erodes the adjacent cartilage and bone, causing permanent structural joint damage.

Critically, RA is not just a joint disease. The same immune dysregulation that attacks joints also affects other organs. RA patients have significantly elevated cardiovascular disease risk — partly from the chronic systemic inflammation, partly from immobility, and partly from some medications. Anaemia, lung involvement (interstitial lung disease in some patients), and eye inflammation (scleritis) are recognised extra-articular features of RA.

Symptoms of Rheumatoid Arthritis — Recognising the Pattern

Joint Symptoms

Morning stiffness lasting more than 1 hour — the most characteristic symptom of RA; distinguishes inflammatory arthritis from osteoarthritis (where morning stiffness lasts less than 30 minutes). The stiffness gradually improves with movement and activity as the day progresses.
Bilateral, symmetrical joint involvement — if the right hand is affected, the left hand will typically also be affected. This symmetry is characteristic of RA.
Joints most commonly affected initially: metacarpophalangeal joints (MCP — the knuckles at the base of the fingers), proximal interphalangeal joints (PIP — the middle finger joints), wrists, metatarsophalangeal joints (MTP — the toe base joints), and ankles
Joint swelling — visible swelling from synovial inflammation; joints feel soft and “boggy” rather than the hard bony swelling of osteoarthritis
Joint warmth and tenderness — inflamed joints feel warm to touch and are tender on pressure

Systemic Symptoms

Fatigue — often profound and disproportionate to activity level; one of the most disabling symptoms for many RA patients
Low-grade fever — intermittent
Weight loss — from systemic inflammation and poor appetite
Anaemia — anaemia of chronic disease is extremely common in RA; contributes to fatigue

Extra-Articular Features

Rheumatoid nodules — firm subcutaneous nodules, typically over the elbow or along the forearm; occur in approximately 20–25% of patients, predominantly those who are RF-positive and have more aggressive disease
Cardiovascular disease — RA patients have approximately double the cardiovascular risk of the general population; monitoring and treatment of hypertension, cholesterol, and diabetes is essential
Interstitial lung disease — in severe or long-standing RA; requires specific evaluation if breathlessness occurs
Eye involvement — keratoconjunctivitis sicca (dry eyes), scleritis

Diagnosing Rheumatoid Arthritis at Suguna Clinic

Clinical Assessment — The 2010 ACR/EULAR Criteria

Dr. Ram Kumar uses the 2010 ACR/EULAR classification criteria for RA, which score four domains: joint involvement pattern, serology (RF and anti-CCP), inflammatory markers (CRP and ESR), and duration of symptoms. A score of 6 or more out of 10 defines RA. The clinical history and examination — which joints, how long, morning stiffness duration, symmetry — provide the framework; blood tests confirm and refine the diagnosis.

Blood Tests

Rheumatoid Factor (RF) — IgM antibody against IgG; positive in approximately 70–80% of RA patients (seropositive RA). RF can also be positive in other conditions (lupus, Sjögren’s, hepatitis C, healthy elderly). A positive RF supports but does not alone diagnose RA; a negative RF does not exclude RA (seronegative RA).
Anti-cyclic citrullinated peptide antibodies (anti-CCP) — more specific for RA than RF (specificity approximately 95%). Anti-CCP positivity predicts more aggressive, erosive disease and typically converts to RF positivity. A high titre of anti-CCP in a patient with compatible symptoms is strong evidence for RA.
CRP (C-Reactive Protein) and ESR — markers of systemic inflammation; elevated in active RA; used for monitoring disease activity and treatment response
Complete blood count — anaemia of chronic disease (normochromic normocytic) is common; thrombocytosis (high platelets) reflects systemic inflammation
Liver function tests (SGPT, SGOT) and renal function — mandatory baseline before starting methotrexate or leflunomide
Thyroid function (TSH) — autoimmune thyroid disease is more common in RA patients; hypothyroidism worsens fatigue. See: Thyroid Treatment in Bandlaguda Jagir.
Fasting glucose and lipid profile — cardiovascular risk assessment; RA patients have higher CV risk. See: Cholesterol Treatment in Bandlaguda Jagir.

Imaging

X-rays of hands, wrists, and feet — baseline imaging to document the presence or absence of erosions; erosions in early disease confirm aggressive RA; serial X-rays track disease progression and treatment response
Ultrasound of joints — detects synovial thickening, synovitis, and erosions earlier than plain X-ray; useful when clinical assessment is uncertain
Chest X-ray — baseline before starting methotrexate; screening for pulmonary RA involvement and TB (important in India before DMARD therapy)

Treating Rheumatoid Arthritis at Suguna Clinic — A Treat-to-Target Approach

The modern standard of RA care is “treat-to-target” — setting a specific treatment goal (remission or low disease activity) and adjusting medications systematically until that target is reached. Disease activity is monitored using composite scores like the DAS28 (Disease Activity Score using 28 joints), which incorporates tender and swollen joint counts, the patient’s global assessment, and the CRP.

Step 1: NSAIDs — Symptom Relief

NSAIDs (naproxen, ibuprofen, celecoxib) provide rapid relief of joint pain and stiffness. They are used for symptomatic control alongside DMARDs but do not slow disease progression or prevent joint erosion. Celecoxib (a COX-2 selective NSAID) is preferred in patients with a history of peptic ulcer disease or at high GI risk. NSAIDs are used at the lowest effective dose for the shortest time needed for symptom control.

Step 2: Corticosteroids — Bridge Therapy and Flare Management

Low-dose prednisolone (5–10mg/day) — used as “bridge therapy” when starting DMARDs (which take 4–8 weeks to achieve full effect), providing anti-inflammatory cover while waiting for DMARDs to work. Also used for short-term flare management.
Deflazacort — an alternative corticosteroid with slightly less weight gain and calcium loss than prednisolone; preferred in diabetic patients and those at high osteoporosis risk
Long-term high-dose corticosteroids are avoided — they cause osteoporosis, cataracts, diabetes, hypertension, and skin atrophy with prolonged use

Step 3: Conventional Synthetic DMARDs — The Cornerstone of RA Treatment

DMARDs (disease-modifying antirheumatic drugs) are the backbone of RA treatment — they slow or halt the immune-mediated joint damage that leads to erosion and deformity. Unlike NSAIDs (which only treat symptoms), DMARDs modify the underlying disease course. They must be started as soon as RA is diagnosed — not after trying NSAIDs for months.

Methotrexate — The Gold Standard DMARD

Methotrexate (MTX) is the first-line DMARD for RA worldwide and in Indian guidelines. Key points:

Dose: 7.5–25mg once weekly (not daily — weekly dosing is critical; daily dosing causes severe toxicity)
Route: Oral tablets initially; subcutaneous injection if oral is poorly tolerated or at higher doses
Folic acid: 5mg once weekly (24 hours after methotrexate dose) — reduces side effects (nausea, mouth ulcers, liver toxicity) without reducing efficacy
Onset of action: 6–12 weeks to see meaningful effect; full effect at 3–6 months
Monitoring: CBC and liver function tests monthly for the first 6 months; every 2–3 months thereafter once stable
Contraindications: Pregnancy (highly teratogenic — women of childbearing age must use contraception); significant liver disease; impaired renal function; alcohol overuse
TB screening before MTX: In India, tuberculosis screening (Mantoux test or IGRA) is recommended before starting methotrexate

Hydroxychloroquine (HCQ)

200–400mg daily. The safest DMARD — minimal monitoring required. Used in mild RA or in combination with methotrexate. Side effects: retinal toxicity with long-term use (annual ophthalmology review for patients on long-term HCQ). Also used for post-chikungunya arthritis and lupus.

Leflunomide

10–20mg daily. An effective alternative to methotrexate in patients who cannot tolerate it. Similar monitoring to methotrexate (CBC, liver function). Long half-life — requires washout procedure before pregnancy.

Sulfasalazine

500mg–2000mg daily, increased gradually. Often used in combination with methotrexate and hydroxychloroquine — the “triple DMARD therapy” (MTX + HCQ + SSZ) is highly effective and comparable to biologic agents in many patients.

Step 4: Biological DMARDs — For Failure of Conventional Therapy

When conventional DMARDs (particularly a methotrexate-based regimen) fail to achieve the treatment target after an adequate trial (usually 3–6 months), biological agents are added. These are advanced immunomodulatory drugs targeting specific inflammatory pathways:

TNF-alpha inhibitors: Adalimumab (Humira, biosimilar Exemptia), etanercept (Enbrel, biosimilar Etacept), certolizumab — most widely used biologics for RA in India
IL-6 inhibitors: Tocilizumab (Actemra) — particularly effective for systemic features and when TNF inhibitors fail
CD20 inhibitor: Rituximab — for refractory RA or where TB risk makes TNF inhibitors less safe
JAK inhibitors: Tofacitinib, baricitinib, upadacitinib — oral targeted synthetic DMARDs; newer options with oral administration convenience

Important for India: All biological DMARDs (particularly TNF inhibitors) require careful tuberculosis screening and prophylaxis before initiation — India is TB-endemic, and biological immunosuppression can reactivate latent TB. Dr. Ram Kumar arranges rheumatology referral for patients requiring biologic agents, where a specialist will conduct TB screening (IGRA or Mantoux + chest X-ray) and initiate isoniazid prophylaxis if needed before biologic treatment.

Monitoring RA Treatment at Suguna Clinic

Ongoing monitoring is essential to assess treatment efficacy, detect toxicity, and adjust medications:

Disease activity assessment at every visit: joint tenderness and swelling count, patient global assessment, CRP
CBC and liver function tests: monthly for first 6 months on methotrexate; then every 2–3 months
Blood pressure: at every visit — RA patients have elevated cardiovascular risk. See: Hypertension Treatment in Bandlaguda Jagir.
Fasting glucose and HbA1c: corticosteroid use raises blood sugar; diabetic patients need closer monitoring
Annual ophthalmology review for patients on long-term hydroxychloroquine (retinal screening)
Bone density (DEXA scan): for patients on long-term corticosteroids; vitamin D and calcium supplementation to prevent corticosteroid-induced osteoporosis
X-rays of hands and feet: annually in active disease; less frequently once remission is achieved

Lifestyle Management — The Non-Pharmacological Foundation

Exercise — Essential, Not Optional

Regular exercise in RA is not merely “good for you in general” — it specifically reduces pain, improves function, reduces fatigue, and reduces cardiovascular risk. Evidence shows that exercise does not worsen joint damage. Best approaches:

Swimming and aquatic exercise — the ideal RA exercise; water buoyancy removes joint loading while allowing full range of motion; warm water reduces stiffness
Walking — 30 minutes daily; low-impact, accessible
Yoga — specifically yoga-for-arthritis programmes; improves flexibility, balance, and pain; Iyengar yoga with props has the best evidence in RA
Range-of-motion exercises — daily gentle flexion and extension of all affected joints to prevent contracture
Avoid high-impact activities (running, jumping) during active flares

Diet — Indian Anti-Inflammatory Guidance

Omega-3 fatty acids — the strongest dietary evidence in RA; omega-3 supplements (fish oil 2–4g/day of EPA+DHA) reduce joint swelling and morning stiffness duration; eating fish (rohu, catla, mackerel) 2–3 times weekly; ground flaxseed (alsi) in rotis
Turmeric (haldi) — curcumin has documented anti-inflammatory activity; 1 tsp daily with black pepper (piperine enhances absorption) in food or warm milk is a genuinely anti-inflammatory daily habit
Ginger (adrak) — gingerols inhibit the same inflammatory pathways as NSAIDs; regular fresh ginger in cooking or ginger tea provides meaningful anti-inflammatory effect
Reduce refined carbohydrates and sugar — pro-inflammatory dietary pattern; replacing white rice with millets and vegetables reduces systemic inflammation
Vitamin D — deficiency (very common in urban Indians) worsens inflammatory arthritis; supplementation (1000–2000 IU/day) is appropriate in most RA patients
Calcium — essential for patients on corticosteroids to protect bone density; dairy, ragi, sesame seeds

Joint Protection Techniques

Use larger, stronger joints for tasks where possible (e.g., carry bags with the forearm rather than the fingers)
Avoid prolonged gripping or pinching activities during flares
Assistive devices — jar openers, adapted cutlery, raised toilet seats — reduce joint stress during daily activities
Splints for wrist and hand joints during active flares — maintain position, reduce pain overnight

When to Refer to a Rheumatologist

Dr. Ram Kumar initiates RA diagnosis and conventional DMARD therapy. Rheumatologist referral is appropriate for:

Failure of conventional DMARD therapy (inadequate response to methotrexate or combination therapy after adequate trial)
Patients requiring biologic or targeted synthetic DMARDs
Diagnostic uncertainty (atypical presentation, suspected overlap with lupus or other connective tissue disease)
Severe, rapidly progressive joint destruction
Extra-articular complications (lung, heart, vasculitis)
Pregnancy planning in a patient on methotrexate or leflunomide (washout and alternative management)

Frequently Asked Questions — Rheumatoid Arthritis Treatment in Bandlaguda, Hyderabad

Is rheumatoid arthritis curable?

RA is not currently curable in the sense of eliminating the autoimmune tendency entirely. However, “remission” — complete or near-complete absence of disease activity — is an achievable and realistic goal for the majority of patients who start treatment early and take their medications consistently. In remission, patients have no significant joint swelling or tenderness, normal inflammatory markers, and continue to live full, active lives. The key to achieving and maintaining remission is: early diagnosis, immediate DMARD initiation, systematic treat-to-target monitoring, and medication adherence.

Do I need to take methotrexate weekly for life?

Once started, methotrexate (and other DMARDs) are typically continued long-term — stopping them allows the immune system to reactivate and the disease to flare, often worse than before. However, in patients who have maintained remission for 12+ months, a cautious, gradual dose reduction under close monitoring can be attempted by Dr. Ram Kumar. Complete discontinuation is considered only in patients with sustained deep remission (typically 2+ years). Even then, Dr. Ram Kumar schedules close follow-up because relapse after stopping DMARDs is common and should be identified and re-treated quickly.

I was told I have “arthritis.” How do I know if it’s rheumatoid arthritis or the normal wear-and-tear type?

The two conditions are very different. Morning stiffness lasting more than one hour is the hallmark of RA; wear-and-tear osteoarthritis produces stiffness lasting less than 30 minutes. RA starts in the small joints of the hands and feet (knuckles, wrist, toe bases); osteoarthritis typically affects the knees, hips, and spine. RA is associated with elevated blood tests (RF, anti-CCP, CRP); osteoarthritis has normal blood tests. Dr. Ram Kumar will assess both clinically and with blood tests to establish which type of arthritis you have — because the treatments are completely different.

Are there any effective Indian or Ayurvedic treatments for RA?

Some Indian/Ayurvedic approaches have evidence as adjuncts — they work alongside conventional DMARDs but should not replace them. Omega-3 fish oil supplements and flaxseed have the strongest evidence for reducing joint inflammation. Turmeric (curcumin) and ginger have demonstrated anti-inflammatory activity in clinical studies. Yoga-for-arthritis programmes (particularly Iyengar yoga) have good evidence for reducing pain and improving function. Shallaki (Boswellia serrata) extract has anti-inflammatory properties demonstrated in osteoarthritis trials. However, no Ayurvedic preparation has been shown to prevent joint erosion or modify disease course the way DMARDs do. Using turmeric and yoga alongside methotrexate is a sound integrated approach; using them instead of methotrexate will result in progressive joint destruction.

Can RA affect pregnancy?

RA has a complex relationship with pregnancy. Many women experience significant improvement of RA symptoms during pregnancy (due to immunomodulatory changes), with flares common in the postpartum period. However, some DMARDs — particularly methotrexate and leflunomide — are absolutely contraindicated in pregnancy due to teratogenicity. Planning pregnancy requires switching to pregnancy-safe medications (hydroxychloroquine is safe; sulfasalazine can be continued) before conception. Dr. Ram Kumar coordinates pre-pregnancy medication planning and monitors closely during and after pregnancy.

Get Expert Rheumatoid Arthritis Care at Suguna Clinic, Bandlaguda Jagir

Rheumatoid arthritis managed early with the right medications achieves remission for most patients. Left untreated or undertreated — which happens frequently when patients rely on painkillers alone — it causes progressive, irreversible joint destruction. Dr. Ram Kumar at Suguna Clinic provides comprehensive RA diagnosis, DMARD initiation and monitoring, cardiovascular risk management, and lifestyle guidance — and ensures timely rheumatology referral for patients who need biological therapy.

📍 Address: Vinayak Nagar, Hydershakote, Bandlaguda Jagir, Telangana 500091
📞 Call / WhatsApp: 09618994555
🌐 Website: www.sugunaclinic.com
📅 Book online or walk in — 7 days a week, same-day consultations available.

Serving patients from Bandlaguda Jagir, Hydershakote, Suncity, Langar House, and all surrounding areas of southern Hyderabad.

Rheumatoid Arthritis Treatment in Bandlaguda Jagir, Hyderabad | Suguna Clinic